Squarepoint
VRCA icon

Squarepoint’s Verrica Pharmaceuticals VRCA Stock Holding History

Squarepoint’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-75,208
Closed -$398K – 5036
2026
Q1 		$398K Buy
75,208
+41,938
+126% +$269K ﹤0.01% 3494
2025
Q4 		$276K Buy
+33,270
New +$184K ﹤0.01% 3664
2025
Q2 		– Sell
-1,129
Closed -$4.99K – 5112
2025
Q1 		$4.99K Buy
+1,129
New +$7.3K ﹤0.01% 4470
2024
Q4 		– Sell
-8,604
Closed -$125K – 5545
2024
Q3 		$125K Buy
+8,604
New +$388K ﹤0.01% 3825
2023
Q4 		– Sell
-1,687
Closed -$65.6K – 4551
2023
Q3 		$65.6K Buy
+1,687
New +$85.7K ﹤0.01% 3610
2023
Q2 		– Sell
-2,340
Closed -$152K – 4057
2023
Q1 		$152K Buy
+2,340
New +$142K ﹤0.01% 2889
2022
Q3 		– Sell
-1,881
Closed -$36K – 3483
2022
Q2 		$36K Buy
+1,881
New +$94.5K ﹤0.01% 2737
2020
Q2 		– Sell
-4,197
Closed -$459K – 2534
2020
Q1 		$459K Sell
4,197
-1,012
-19% -$133K 0.01% 1091
2019
Q4 		$828K Buy
+5,209
New +$769K ﹤0.01% 1455

Other funds holding VRCA

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $149M AUM 39.81% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mariner
Mariner Overland Park, Kansas $95.2B AUM 32.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Squarepoint's VRCA Position: Q2 2026 in Review

Squarepoint sold out of Verrica Pharmaceuticals (VRCA) in Q2 2026, closing a stake of 75,208 shares — an estimated $398K sold.

Squarepoint first reported a position in VRCA in Q4 2019 and held it in 9 quarters. The position peaked at $828K in Q4 2019. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.

  • Squarepoint reported no remaining Verrica Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Squarepoint sold 75,208 Verrica Pharmaceuticals shares in Q2 2026, an estimated $398K.
  • Squarepoint first reported a position in Verrica Pharmaceuticals in Q4 2019 and held it in 9 quarters.
  • Squarepoint's Verrica Pharmaceuticals position peaked at $828K in Q4 2019.
  • 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.